What the FDA labels say about taking them together
Everolimus and itraconazole
Everolimus's FDA label (Zortress) of February 12, 2026 names itraconazole in its drug interactions section, and itraconazole's label names everolimus too. The everolimus label: “Concurrent treatment with strong inhibitors and inducers of CYP3A4 is not recommended.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the itraconazole FDA label on DailyMed (effective July 13, 2026, Janssen Pharmaceuticals, Inc.).
What does the everolimus label say about itraconazole?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsConcurrent treatment with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) and inducers (e.g., rifampin, rifabutin) of CYP3A4 is not recommended.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsInhibitors and Inducers of CYP3A4 Coadministration of Zortress with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) or strong CYP3A4 inducers (e.g., rifampin, rifabutin) is not recommended without close monitoring of everolimus whole blood trough concentrations [see Drug Interactions (7)].
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the itraconazole label say about everolimus?
Itraconazole label, drug interactionsEverolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after SPORANOX ® treatment.
Source: FDA drug label (Tolsura, NDA208901), Mayne Pharma Commercial LLC, effective April 23, 2025 (SPL set 306352d1-9d5a-49ad-b72d-893b99546861), via openFDA
Source: FDA drug label (SPORANOX), Janssen Pharmaceuticals, Inc., effective July 13, 2026 (SPL set a4d555fa-787c-40fb-bb7d-b0d4f7318fd0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Itraconazole | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | Fungal infections |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $0.910 per capsule 100 mg capsule |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once